

Patient Name	: Mrs. ANKITA DUTTA	Collected	: 11/Oct/2025 01:19PM
Age/Gender	: 34 Y 0 M 0 D /F	Received	: 12/Oct/2025 12:08PM
UHID/MR No	: DNB.R.0000069903	Reported	: 13/Oct/2025 06:27PM
Visit ID	: DNBROPV72226	Status	: Final Report
Ref Doctor	: DR GOPAL KALITA	Client Name	: PCC NALBARI ASSAM
IP/OP NO	:	Center location	: GUWAHATI

DEPARTMENT OF BIOCHEMISTRY.
MATERNAL SCREENING SECOND TRIMESTER- QUADRUPLE MARKER.

MATERNAL SCREENING SECOND TRIMESTER- QUADRUPLE MARKER, SERUM

*Method - Time resolved Immunofluorometry on AutoDelfia * Risk ratio calculated using LifeCycle 7.0

MATERNAL DETAILS		RESULT	UNITS	
NUMBER OF FETUSES		1		
WEIGHT		53	Kg	
H/O SMOKING		NO		
ETHNIC ORIGIN		ASIAN		
AGE AT TERM		34/04	YEARS/MONTHS	
INSULIN DEPENDENT DIABETES		NO		

USG DETAILS				
DATE OF ULTRASOUND		14/09/2025		
GESTATIONAL AGE ON USG		21/1	WEEKS/DAYS	

BIOCHEMICAL RESULTS		RESULT	UNITS	CORR. MOM	METHOD
ALPHA FETOPROTEIN (AFP)		50.98	U/mL	0.78	Immunofluorometry
FREE BETA HCG		48.79	ng/mL	6.38	Immunofluorometry
UNCONJUGATED E3 (uE3)		12.59	nmol/L	1.41	Immunofluorometry
INHIBIN-A		473.79	pg/ml	1.34	Immunofluorometry

DISORDER	RISK RATIO	RISK CATEGORY	SCREEN RESULT
DOWN'S SYNDROME	1:42	INCREASED	SCREEN POSITIVE
EDWARD'S SYNDROME	1:19209	LOW	SCREEN NEGATIVE
PATAU'S SYNDROME	1:100000	LOW	SCREEN NEGATIVE
OPEN NEURAL TUBE/ABDOMINAL WALL DEFECT		LOW	SCREEN NEGATIVE

Comment: Increased risk for T21 has been noted. Advice: Genetic counselling and NIPT or invasive test for further management.

Interpretation:-

1. The risks are calculated based on ultrasound gestational age, biochemical results, NT measurement, patient



Dr. Maita Sujana Reddy
M.B.B.S, M.D (Biochemistry)
Consultant Biochemist

SIN No: IF00759814

This test has been performed at Apollo Health & Lifestyle Ltd, Global Reference Laboratory, Hyderabad



Apollo Health and Lifestyle Limited

(CIN - U85110TG2000PLC115819)

Corporate Office: 7-1-617/A, 7th Floor, Imperial Towers, Ameerpet, Hyderabad-500016, Telangana

Patient Name : Mrs.ANKITA DUTTA
 Age/Gender : 34 Y 0 M 0 D /F
 UHID/MR No : DNB.R.0000069903
 Visit ID : DNBROPV72226
 Ref Doctor : DR GOPAL KALITA
 IP/OP NO :

Collected : 11/Oct/2025 01:19PM
 Received : 12/Oct/2025 12:08PM
 Reported : 13/Oct/2025 06:27PM
 Status : Final Report
 Client Name : PCC NALBARI ASSAM
 Center location : GUWAHATI

DEPARTMENT OF BIOCHEMISTRY.

MATERNAL SCREENING SECOND TRIMESTER- QUADRUPLE MARKER.

demographics and other risk factors such as IDD.

2. Patient specific risks are generated as analytical MoM (Multiples of Median) values, using Fetal Medicine Foundation (FMF) approved assays and software LIFECYCLE version 7.0 from Perkin Elmer.
3. A screen positive result occurs when the risk for Down's syndrome- exceeds 1:250 and MOM pattern shows HCG- above 1.91, Inhibin A- above 2.0, uE3- below 0.61, AFP- below 0.71
4. A screen positive result occurs when risk for Trisomy 13/18- exceeds 1:100 and MOM pattern shows HCG- below 0.36, uE3- below 0.4, AFP- below 0.65
5. A screen positive result occurs when risk for Open Neural tube defect- AFP MOM exceeds 2.5


Limitations: -

1. The results of this test represent only risks and not diagnostic outcomes. Increased risk does not mean that the baby is affected, and further tests must be performed before a firm diagnosis can be made. A low risk does not exclude possibility of Down's syndrome or other abnormalities, as risk assessment does not detect all affected pregnancies.
2. If the history provided is not correct, it is advisable to ask for repeat risk calculations.
3. Isolated alterations in hormonal values can contribute to statistical risk calculation. Following Maternal factors (adversely affecting risk calculation are gestational hypertension, liver diseases, renal diseases, ovarian tumor, uterine fibroids) and/or Fetal & placental factors (adversely affecting risk calculation are congenital adrenal hyperplasia, IUGR, abdominal wall defects, smith levli opitz syndrome, fetal demise, placental anomalies, retroplacental hemorrhage). These should be considered during case specific interpretation accordingly.

Associated Tests: -

1. NIPT- Non-invasive Prenatal Screening test - from maternal blood for aneuploidy screening.

*** End Of Report ***



Dr. Matta Sujana Reddy
Dr. Matta Sujana Reddy
M.B.B.S, M.D (Biochemistry)
Consultant Biochemist

SIN No:IF00759814

This test has been performed at Apollo Health & Lifestyle Ltd, Global Reference Laboratory, Hyderabad

Apollo Health and Lifestyle Limited

(CIN - U85110TG2000PLC115819)

Corporate Office: 7-1-617/A, 7th Floor, Imperial Towers, Ameerpet, Hyderabad-500016, Telangana

PATIENT REPORT - Mrs.ANKITA DUTTA

13/10/2025

Requestor: -, DR GOPAL KALITA

REQUESTOR TYPE: Hospital	REQUESTOR: -	DOCTOR: DR GOPAL KALITA	FACILITY: -
REQUESTOR CODE: DR GOPAL KALITA	REQUESTOR PHONE 1: -		

Patient DNBR.0000069903: -, Mrs.ANKITA DUTTA

PATIENT ID: DNBR.0000069903	LAST NAME: -	FIRST NAME: Mrs.ANKITA DUTTA	BIRTH DATE: 27/09/1991
ETHNICITY: Asian	ADDRESS 1: -	CITY: -	POSTAL CODE: -

Pregnancy, Calculated EDD: 13/02/2026 (MAEDD: 34.38)

MAEDD: 34.38	CALCULATED EDD: 13/02/2026	GEST. DATE: 09/05/2025	SELECTED GEST. METHOD: BPD
LMP DATE: 10/04/2025	SMOKING STATUS: Non smoker	INSULIN DEP. DIABETIC: No	NO. OF FETUSES: 1
MONOZYGOS: No	CHORIONICITY: -	CORRECTED BY CHORIONICITY: -	FERTILIZATION DATE: -
ASSISTANCE METHOD: -	TRANSFER DATE: -	EGG EXTRACTION DATE: -	EGG DONOR DOB: -
AGE AT EXTRACTION: -	PAST T21 - DOWN'S SYNDROME: -	PAST T18 - EDWARDS' SYNDROME: -	PAST T13 - PATAU'S SYNDROME: -
PAST CDLS - CORNELIA DE LANGE SYNDROME: -	PAST SLOS - SMITH-LEMLI-OPITZ SYNDROME: -	PAST TR - TRIPLOIDY: -	PAST TS - TURNER'S SYNDROME: -
RISK ASSESSED: At term	SCREENING PROTOCOL: Screening_4.0		

Biochemistry

SAMPLE ID: IF00759814	SPECIMEN COLLECTED: 07/10/2025	WEIGHT [KG]: 53	GEST. AT SAMPLE DATE (W + D): 21 w 4 d
SAMPLE TYPE: -			

Ultrasound

SCAN DATE: 14/09/2025	CRL: -	BPD: 50	HC: -
GEST. AT SAMPLE DATE (W + D): 21 w 1 d	CRL (#2): -	BPD (#2): -	HC (#2): -
GEST. AT MANUAL ENTRY (W + D): 0 w 0 d	SAMPLE TYPE: -	WEIGHT [KG]: -	

Tests

TEST	SAMPLE ID	DATE	GEST. AT SAMPLE DATE (W + D)	VALUE	UNIT	CORR. MOM	WEIGHT [KG]
AFP (Signed)	IF00759814	07/10/2025	21 w 4 d	50.99	U/mL	0.78	53
hCGB (Signed)	IF00759814	07/10/2025	21 w 4 d	48.8	ng/mL	6.39	53
INHIBIN (Signed)	IF00759814	07/10/2025	21 w 4 d	473.8	pg/mL	1.35	53
UE3UPD (Signed)	IF00759814	07/10/2025	21 w 4 d	12.6	nmol/L	1.41	53

RISKS SIGNED BY:

REPORT CREATED BY:

Shyamala


REPORT CREATED AT:

13/10/2025 10:52 AM

PATIENT REPORT - Mrs.ANKITA DUTTA

13/10/2025

Risks, Risk assessed: At term					
RISK NAME: T21 (Calculated)	RISK RESULT: Increased	RISK: 1:42	TWIN RISK RESULT:	TWIN RISK:	AGE RISK: 1:486
RECOMMENDATION:	To be correlated clinically.				
RISK NAME: T18 (Calculated)	RISK RESULT: Low	RISK: 1:19209	TWIN RISK RESULT:	TWIN RISK:	AGE RISK: 1:4372
RISK NAME: T13 (Calculated)	RISK RESULT: Low	RISK: 1:100000	TWIN RISK RESULT:	TWIN RISK:	AGE RISK: 1:100
RISK NAME: NTD (Calculated)	RISK RESULT: Low	RISK: -	TWIN RISK RESULT:	TWIN RISK:	AGE RISK: 1:13122
					CUT-OFF: 2.5



PLEASE NOTE:

RISKS SIGNED BY:

REPORT CREATED BY:

REPORT CREATED AT:
13/10/2025 10:52 AM

Shyamala

Patient Name	: Mrs.ANKITA DUTTA	Collected	: 11/Oct/2025 01:19PM
Age/Gender	: 34 Y 0 M 0 D /F	Received	: 12/Oct/2025 12:08PM
UHID/MR No	: DNBR.0000069903	Reported	: 13/Oct/2025 06:27PM
Visit ID	: DNBROPV72226	Status	: Final Report
Ref Doctor	: DR GOPAL KALITA	Client Name	: PCC NALBARI ASSAM
IP/OP NO	:	Center location	: ,GUWAHATI

TERMS AND CONDITIONS GOVERNING THIS REPORT

1. Reported results are for information and interpretation of the referring doctor or such other medical professionals, who understand reporting units, reference ranges and limitation of technologies. Laboratories not be responsible for any interpretation whatsoever
2. This is computer generated medical diagnostics report that has been validated by an Authorized Medical Practitioner/Doctor. The report does not need physical signature.
3. Partial reproduction of this report is not valid and should not be resorted to draw any conclusion.
4. In the case you are not the intended recipient of this report. Please immediately return the same to the concerned issuing desk. Any disclosure, copy or distribution of any contents of this report, is unlawful and is strictly prohibited.
5. Results delays may occur due to unforeseen circumstances such as non-availability of kits, equipment breakdown, natural calamities, IT downtime, logistic delays or any other unavoidable event. For certain tests based on analyte stability, criticality of results and in the interest of patient for having appropriate medical diagnosis, the same test may be outsourced to other accredited laboratory.
6. It is presumed that the tests performed are, on the specimen / sample being to the patient named or identified and the verifications of particulars have been confirmed by the patient or his / her representative at the point of generation of said specimen
7. The reported results are restricted to the given specimen only. Results may vary from lab to lab and from time to time for the same parameter for the same patient (within subject biological variation).
8. The patient details along with their results in certain cases like notifiable diseases and as per local regulatory requirements will be communicated to the assigned regulatory bodies
9. The patient samples can be used as part of internal quality control, test verification, data analysis purposes within the testing scope of the laboratory.
10. This report is not valid for medico legal purposes. It is performed to facilitate medical diagnosis only


Dr.Matta Sujana Reddy
M.B.B.S,M.D(Biochemistry)
Consultant Biochemist

SIN No:IF00759814

This test has been performed at Apollo Health & Lifestyle Ltd, Global Reference Laboratory, Hyderabad



Apollo Health and Lifestyle Limited

(CIN - U85110TG2000PLC115819)

Corporate Office: 7-1-617/A, 7th Floor, Imperial Towers, Ameerpet, Hyderabad-500016, Telangana

Ph No: 040-4904 7777 | www.apolloh.com | Email ID:enquiry@apolloh.com